In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Full approval will depend on verification of clinical benefit in a confirmatory trial
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
